AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06774170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured follow-up intervention
Description: The intervention has been created in light of the studies including type 1 and type 2 diabetes patients and experiences of the project team with patients after PD. Theoretical background of the intervention is based on the interventions developed for glucose management in type 1 and type 2 diabetes patients and the effect of the intervention will be evaluated by using the plan-do-check-act model.
Study NCT05636735 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: evaluation of self -confidence
Study NCT06367114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ssCART-19
Description: Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied.
Study NCT05004012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetically Controlled Capsule Endoscopy
Description: This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
Study NCT06367114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study NCT06367114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study NCT05676645 — intervention group
Intervention type: DRUG
Intervention: Artemether-lumefantrine
Description: National policy recommendation for treatment of uncomplicated malaria in Uganda
Study NCT05789342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681
Description: GP681, tablet, oral
Study NCT05789342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin, tablet, oral
Study NCT05789342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin, tablet, oral
Study NCT05789342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole, capsule, oral
Study NCT05789342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir, capsule, oral
Study NCT01604200 — intervention group
Intervention type: BEHAVIORAL
Intervention: focus group
Description: key informant review
Study NCT05099276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Pill
Description: 1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
Study NCT05099276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two
Study NCT04831944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered orally after 8 hours of fasting.
Study NCT05176678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1 gram of a protein hydrolysate
Description: After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
Study NCT05176678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 grams of a protein hydrolysate
Description: After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
Study NCT05176678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4 grams of a protein hydrolysate
Description: After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
Study NCT05176678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 8 grams of a protein hydrolysate
Description: After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
Study NCT06774508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFE+cog
Description: Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Simultaneous cognitive exercises are added to static and dynamic balance exercises. Relative exercise intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
Study NCT06774508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIFE
Description: Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Relative exercises intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
Study NCT04055389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin III
Description: Patients with reversal of flow or sluggish flow in the main portal vein (\<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life \~4 days) at a weight-based dosage according to the following formula:~\[Desired level of AT (100%) - Subject level of AT (%)\] \* subject weight (kg) 1.4~or placebo for 24 weeks of therapy.
Study NCT04055389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No study drug
Study NCT04844346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol mini drinks
Description: Oat milk based mini drinks (100 mL) containing 2g plant stanols each (delivered as plant stanol esters).
Study NCT04844346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mini drinks
Description: Oat milk based mini drinks (100 mL) without added plant stanols (delivered as plant stanol esters).
Study NCT04844346 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 vaccine
Description: First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Study NCT06777927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
Study NCT05178134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etvax
Description: Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl).
Study NCT05178134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etvax
Description: Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
Study NCT04943588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCV RNA (PCR)
Description: We will test HCV positive patients after treatment to observe if they achieve SVR
Study NCT04943588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HCV Antibody test (Point of care)
Description: HCV antibody test used to establish if patients have had or are actively infected with HCV
Study NCT04943588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AST/ALT and platelets measurement
Description: AST/ALT and platelets to determine APRI score
Study NCT05641454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ElevATP supplement
Description: ElevATP supplement containing apple and ancient peat extract
Study NCT05641454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study NCT04844346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: First dose of one of the COVID-19 vaccines. Participants have to wait until they are invited to receive the vaccine by the government; this study does not interfere with national planning of the vaccines.
Study NCT06777927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The subjects would be doing treadmill training within moderate intensity target heart rate.
Study NCT06777927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The subjects would not be given any intervention and would be used as controls.
Study NCT05188612 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Observational (registry)
Description: Observational (Patient Registry)
Study NCT05375799 — intervention group
Intervention type: OTHER
Intervention: Clinical Observation
Description: This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO.~All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects ).
Study NCT04711577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Track clinician-determined symptoms
Description: Participants will track clinician-determined symptoms
Study NCT04711577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Track clinician-determined and self-determined symptoms
Description: Participants will track clinician-determined symptoms and a self-determined symptom
Study NCT04967703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Patients received ultrasound therapy protocol with the following parameters (1 MHz frequency, intensity of 1.5 W/cm2 and use of continuous mode of ultrasound for 5 minutes), in addition to a conventional physiotherapy program consisting of calf muscles stretching, plantar fascia stretch, strengthening exercises and manual massage for 3 sessions per week, for 4 weeks
Study NCT04967703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: Patients received radial shock wave therapy protocol with the following parameters (1) the energy level was 0.12 mJ/mm2 equivalent to 2.5 bar intensity, (2) the number of shoots was 2000, (3) the frequency was 8 Hz, in addition to the same conventional physiotherapy program given for group A
Study NCT04967703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group C
Description: Patients received both ultrasound and radial shock wave therapy, in addition to the same conventional physiotherapy program given for group A
Study NCT05849753 — intervention group
Intervention type: DEVICE
Intervention: Advanced artificial pancreas closed-loop technology
Description: Study is an observational capture of data in patients that qualify, before and after the use of any FDA-approved closed-loop system of Subject's/Family's choosing that uses a CGM that does not require fingerprick calibrations. Devices prescribed available through their insurance (including Medicaid).
Study NCT04538053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cefalexin only
Description: High-dose oral cefalexin
Study NCT04538053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV cefazolin or IV flucloxacillin followed by oral cefalexin
Description: Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin
Study NCT05200416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heylo
Description: Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
Study NCT05831072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-cognitive oriented group program
Description: Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
Study NCT06440759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris filter
Description: Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
Study NCT06440759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: M100 filter
Description: Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
Study NCT04449809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: 3x per week group monitored group exercise sessions
Study NCT04808895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: administration of one tablet daily for 15 days. On the first day a loading dose of 300 mg will be administered
Study NCT04808895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of one tablet daily for 15 days. On the first day 3 tablets will be administered
Study NCT04607616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline sessions TAU
Description: TAU consists of sessions lasting around one/one and a half hour ; the consultant is practicing as usual. The interventions focus on child's behavior, parent infant relationship, with moments of play with the child, advices, informations about child development and Autism.
Study NCT04607616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive guidance therapy
Description: The objective is to reinforce the identification, deciphering, interpretation, and answer to child's signals by the parent, in order to to promote a synchronous and attuned response to the child's needs.~Sessions last around one/one and a half hour. Parent plays 7-10 minutes with the child, in the presence of the therapist, with toys chosen according to the child's developmental stage. Then therapist proposes an immediate viewing of the play session. The therapist selects short moments of positive interaction. He has determined a  focus , depending on the play, previous sessions, the child's difficulties and parent's interventions. He accompanies, guides and supports the parent to describe the interaction, the alternance in play, joint attention, shared affect, in a co-construction: the parent discovers the child's and his own skills.
Study NCT05200416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heylo
Description: Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
Study NCT04607616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Developmental and diagnostic assessments
Description: MSEL, CARS, ECAR, CIM10, DMS5, ADOS, ADIR
Study NCT04607616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developmental assessment -Parental scales
Description: Vineland II, IFDC, IDE
Study NCT05200416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
Study NCT05200416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
Study NCT04426214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: We will apply tDCS in combination with cognitive training. All participants receive cognitive training, and will be randomized to receive either active or sham tDCS
Study NCT04426214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: cognitive training on computer
Study NCT04426214 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: cognitive training on computer
Study NCT06254872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentors
Description: Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
Study NCT04902443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.
Study NCT04902443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
Study NCT05092022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evalyn Self-Sampling Brush
Description: A self-sampling brush to collect cervical cells for screening purposes.
Study NCT05578976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study NCT05578976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous (IV) Injection
Study NCT04607616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Description: Interpretative Phenomenological Analysis. Parents' semi structured interview about the Interactive Guidance experience. Qualitative analysis of transcripts (recurrent themes, meta themes).
Study NCT06726044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitaion after ACL reconstruction
Description: The SR group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes and was conducted by the same therapist.~After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests. Before rehabilitation involving kinesiotherapy (two weeks post-surgery), the following measurements were conducted:~Height and body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation~After the rehabilitation the following measurements and assessments were conducted:~Body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation Evaluation of the strength of knee extensor and flexor muscles under isokinetic conditions Evaluation of knee extensor strength under inertial conditions Postural stability assessment
Study NCT06726044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitaion after ACL reconstruction
Description: The SR group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes and was conducted by the same therapist.~After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests. Before rehabilitation involving kinesiotherapy (two weeks post-surgery), the following measurements were conducted:~Height and body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation~After the rehabilitation the following measurements and assessments were conducted:~Body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation Evaluation of the strength of knee extensor and flexor muscles under isokinetic conditions Evaluation of knee extensor strength under inertial conditions Postural stability assessment
Study NCT06726044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitaion after ACL reconstruction plus inertial exercises
Description: The SR+I group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks including inertial exercises. Each session lasted approximately 70 minutes and was conducted by the same therapist.~Subjects also performed inertial exercises from the fifth week of rehabilitation. These exercises were conducted on an InerKnee. The inertial exercises protocol included: knee extension exercises performed in a seated position for the operated leg, 4 sets of exercises, each lasting 15 seconds individually, adjusted resistance to maintain a 1-second extension cycle, passive rest periods of 2 minutes between sets After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests the same as in SR group.